FDA lifts hold on NeoRx' STR (Skeletal Targeted Radiotherapy) programme:
This article was originally published in Clinica
The US FDA has lifted its hold on the further development of NeoRx' Skeletal Targeted Radiotherapy (STR) product for treating multiple myeloma, a cancer of the bone marrow. The agency's decision follows NeoRx's submission of data from a dosimetry study of STR, which had been requested by the FDA. The Seattle, Washington firm said that it intended to submit a phase III study protocol before the end of the second quarter of 2003 for review by the FDA. Three-year survival data on the STR phase I/II patients is expected to become available by the end of this year.